Brought to you by 
Anaphore partners Atrimers with Mitsubishi Tanabe
23 Feb 2023
Executive Summary
Anaphore Inc. (protein therapies for cancer and immune conditions) will use its Atrimer technology to discover new autoimmune treatments for Mitsubishi Tanabe Pharma Corp. The companies will initially focus on rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Anaphore partners Atrimers with Mitsubishi Tanabe
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice